[1] DONG Fen, ZHANG Biao, SHAN Guangliang. Distribution and risk factors of thyroid cancer in China[J]. China Oncology, 26, 47-52(2016).

[2] Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis[J]. Nuclear Medicine Review Central & Eastern Europe, 15, 120-123(2012).

[3] Sacks W, Waxman A D. Radioactive iodine therapy[M]. Thyroid Cancer, 243-270(2012).

[4] United N. 2000 Report to the general assembly with scientific annexes[R](2001).

[5] Barquero R, Basurto F, Nuñez C et al. Liquid discharges from patients undergoing 131I treatments[J]. Journal of Environmental Radioactivity, 99, 1530-1534(2008).

[10] DENG Fei, ZHOU Ruidong, JIANG Lan et al. Problems on emission management of nuclear medicine wastewater containing iodine[J]. Radiation Protection, 38, 252-257(2018).

[15] Driver I, Packer S. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma[J]. Nuclear Medicine Communications, 22, 1129-1132(2001).

[16] Ward W F, Henkin R E, Bova D, Dillehay G L, al et, eds. Basic principles of radiation biology[A]. Nuclear medicine, 507-522(2006).

[17] Clarke SEM, Murray IPC, Ell P J, eds. Radioiodine therapy of the thyroid[A]. Nuclear medicine in clinical diagnosis and treatment, 833-845(1994).